Bacteriophage Therapy Market to Reach USD 2.7 Billion by 2034

The market is projected to expand at a CAGR of 8.4% from 2024 to 2034, driven by rising antibiotic resistance, precision-microbiome research, and renewed global focus on infectious disease control.

Pune, India - November 2025 - Exactitude Consultancy announces that the Global Bacteriophage Therapy Market is entering a critical growth phase as the world seeks sustainable and precise alternatives to traditional antibiotics. The growing prevalence of multi-drug-resistant (MDR) bacterial infections and hospital-acquired infections is fueling interest in phage-based therapeutics, especially across the U.S., Europe, and Asia.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72614

Key Takeaways
• The global bacteriophage therapy market was valued at USD 1.2 billion in 2024 and is expected to reach USD 2.7 billion by 2034, growing at a CAGR of 8.4%.
• Phage therapy is gaining traction as an adaptive and highly specific antimicrobial strategy targeting resistant bacterial strains.
• Expansion of clinical trials in wound care, respiratory infections, and urinary tract infections (UTIs) is accelerating market maturity.
• North America leads global revenue, while Europe and Asia-Pacific are rapidly advancing regulatory and R&D frameworks.

Market Overview
Bacteriophage therapy uses viruses that infect and destroy bacteria-offering a precision-targeted, self-replicating solution for infections where antibiotics fail. The technology leverages naturally occurring phages to eliminate specific bacterial pathogens without harming beneficial microbiota, making it a promising tool against antimicrobial resistance (AMR).

Phage research has progressed from compassionate-use cases to structured clinical development. Advancements in genome sequencing, synthetic biology, and CRISPR-based editing are enabling the engineering of customized phage cocktails that can adapt to bacterial mutations. Biotech start-ups and research institutions are actively developing scalable manufacturing and regulatory pathways for therapeutic phages.

Segment Insights
• By Therapy Type:
o Phage Cocktails - Largest segment; designed to target multiple bacterial strains simultaneously.
o Monophage Therapy - Applied in precision treatments for specific bacterial infections.
o Genetically Modified and Synthetic Phages - Emerging segment with enhanced stability and specificity.

• By Application:
o Wound and Skin Infections
o Respiratory Tract Infections
o Urinary Tract Infections (UTIs)
o Gastrointestinal Infections
o Others (Sepsis, Otitis, Osteomyelitis)

• By Route of Administration:
o Topical
o Oral
o Injectable

• By End User:
o Hospitals and Specialty Clinics
o Research Institutes
o Pharmaceutical and Biotechnology Companies

• By Region:
o North America - Leading share; strong funding and regulatory pilot frameworks.
o Europe - Advancing clinical trials under EMA adaptive pathways.
o Asia-Pacific - Fastest CAGR, driven by AMR challenges and government-funded R&D.
o Latin America & Middle East - Emerging phage-production capabilities.

Explore Full Report here: https://exactitudeconsultancy.com/reports/72614/bacteriophage-therapy-market

Recent Developments
• Adaptive Phage Therapeutics (APT) expanded its adaptive phage library and partnered with U.S. military health systems to address resistant wound infections.
• Intralytix Inc. received regulatory clearance for commercial phage-based food-safety products, paving the way for human therapeutic use.
• Pherecydes Pharma initiated late-stage trials for Staphylococcus aureus and Pseudomonas aeruginosa infections in collaboration with European hospitals.
• Armata Pharmaceuticals announced positive Phase I/II data for intravenous phage therapy targeting chronic lung infections in cystic fibrosis patients.
• Government-funded programs across the U.K., France, and India are establishing national phage-bank repositories to facilitate clinical research.

Expert Insight
"Bacteriophage therapy represents the revival of a century-old concept re-engineered through genomics and synthetic biology. It offers hope in an era where antimicrobial resistance threatens global healthcare systems," said the biotechnology research team at Exactitude Consultancy.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72614

Market Drivers
• Escalating global threat of antimicrobial resistance (AMR).
• Increasing failure rates of broad-spectrum antibiotics.
• Technological advances in phage selection, genome sequencing, and bioengineering.
• Expanding investment by biotech start-ups and research consortia.
• Regulatory recognition of phage therapy under adaptive-pathway frameworks.

Market Challenges
• Lack of standardized manufacturing and quality-control guidelines.
• Limited large-scale clinical validation for chronic infections.
• High cost and complexity of personalized phage formulation.
• Evolving global regulatory landscape requiring harmonization.

Government and Policy Initiatives
Global health authorities, including the WHO and CDC, are emphasizing bacteriophage therapy in AMR-mitigation strategies. The U.S. FDA has issued compassionate-use authorizations for phage therapies, while the European Medicines Agency (EMA) supports adaptive regulatory pathways for phage products. In Asia, government-funded initiatives in India, South Korea, and China are supporting the establishment of GMP-certified phage-manufacturing facilities.

Market Forecast
The global bacteriophage therapy market is projected to grow at a CAGR of 8.4% through 2034, reaching USD 2.7 billion. Growth will be led by hospital-based phage therapy programs, synthetic biology innovation, and rising collaboration between academia and biotech manufacturers.

Conclusion
The bacteriophage therapy market is set to become a cornerstone of next-generation infectious-disease management. As phage engineering, delivery optimization, and regulatory clarity evolve, phage-based therapeutics are expected to complement or even replace antibiotics in critical care and chronic infection scenarios. The coming decade marks a pivotal shift toward biologically intelligent antimicrobials.

This report is also available in the following languages : Japanese (バクテリオファージ療法市場), Korean (박테리오파지 치료제 시장), Chinese (噬菌体疗法市场), French (Marché de la phagothérapie), German (Markt für Bakteriophagentherapie), and Italian (Mercato della terapia batteriofagica), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72614/bacteriophage-therapy-market#request-a-sample

Related Reports by Exactitude Consultancy

Head and Neck cancer Market
https://exactitudeconsultancy.com/reports/70860/head-and-neck-cancer-market

Basal Cell Neoplasms Market
https://exactitudeconsultancy.com/reports/70903/basal-cell-neoplasms-market

Bowen's Disease Market
https://exactitudeconsultancy.com/reports/71179/bowen-s-disease-market

Actinic Keratosis Market
https://exactitudeconsultancy.com/reports/71368/actinic-keratosis-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.